In Situ Forming Injectable Hydrogel For Encapsulation Of Nanoiguratimod And Sustained Release Of Therapeutics
Received 5 May 2019
Accepted for publication 21 October 2019
Published 6 November 2019 Volume 2019:14 Pages 8725—8738
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Mian Wang
Zhenzhen Ma,1,* Cheng Tao,2,* Lin Sun,1 Shengbei Qi,2 Yuan Le,2,3 Jiexin Wang,2–4 Changhong Li,1 Xiangyuan Liu,1 Jianjun Zhang,2 Jinxia Zhao1
1Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, People’s Republic of China; 2College of Chemical Engineering, Beijing University of Chemical Technology, Beijing 100029, People’s Republic of China; 3Research Center of the Ministry of Education for High Gravity Engineering and Technology, Beijing University of Chemical Technology, Beijing 100029, People’s Republic of China; 4Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing 100029, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jianjun Zhang; Jinxia Zhao Email [email protected]; [email protected]
Background: Iguratimod (IGUR) is a novel disease-modifying antirheumatic drug used for treating rheumatoid arthritis (RA). To improve its bioavailability and to alleviate gastrointestinal side effects, we changed the formulation into nanoiguratimod-loaded hydrogel (NanoIGUR-loaded hydrogel) composites for sustained release of therapeutics.
Methods: IGUR was first encapsulated in biodegradable polyvinyl alcohol micelle by liquid antisolvent precipitation (LAP) technology, and then loaded into an in situ injectable hyaluronic acid hydrogel, which was cross-linked by PEG (Thiol)2 (HS-PEG-SH) through Michael addition reaction. In vitro, the biological effects (proliferation, migration, and invasion) of NanoIGUR-loaded hydrogel on fibroblast-like synoviocytes (RA-FLS) from RA patients were evaluated. In vivo, the pharmacokinetics of NanoIGUR-loaded hydrogel was assessed and the efficacy of NanoIGUR-loaded hydrogel in treating collagen-induced arthritis (CIA) rats was evaluated.
Results: By the LAP technique, we acquired the amorphous form nanoiguratimod, with an average size of 458 nm, which had higher dissolution rates and higher stability. The release of IGUR from hydrogel composite in PBS was gradual and sustained for up to 72 hrs compared with nanoiguratimod. Different concentrations of NanoIGUR-loaded hydrogel inhibited the proliferation, migration, and invasion of RA-FLS. The pharmacokinetic parameters showed better bioavailability and longer half-life time with NanoIGUR-loaded hydrogel by subcutaneous administration than oral raw iguratimod. Animal experiments confirmed that subcutaneous injection of NanoIGUR-loaded hydrogel (10 mg/kg every 3 days) and oral raw iguratimod (10mg/kg daily) showed similar efficacy in decreasing arthritis index score, pathological score, and expression of inflammatory cytokines.
Conclusion: Overall, we demonstrate that NanoIGUR-loaded hydrogel provides a new route of administration and extends the administration interval. It could be a promising drug-delivery approach in the management of RA.
Keywords: iguratimod, nanoparticles, injectable hydrogel, rheumatoid arthritis, drug sustained-release system
Rheumatoid arthritis (RA) is a chronic inflammatory and autoimmune disease characterized by symmetrical, progressive, and aggressive polyarthritis.1 The disease invades articular cartilage and surrounding soft tissues, resulting in the destruction of articular cartilage, bone, and joint capsule, eventually leading to joint deformity, physical disability, and loss of function, which significantly reduces the quality of life of patients.2,3
Early treatment is especially important for the prognosis of RA.4 Drugs for treating RA mainly include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), glucocorticoids, and biological agents. Traditional DMARDs, including leflunomide, methotrexate (MTX), and sulfasalazine, have been widely used in clinical practice and show a certain degree of therapeutic efficacy. However, there is still a significant proportion of patients with RA who do not achieve clinical remission with these traditional DMARDs.5 Among biologics commonly used in RA, tumor necrosis factor alpha (TNF-α) inhibitors were the most frequently used; however, about 20% to 40% of RA patients treated with a TNF-α inhibitor fail to achieve a 20% improvement in American College of Rheumatology (ACR20) criteria, and moreover lose response over time, due to secondary failure or acquired therapeutic resistance,6 and some may experience adverse events such as infections.7 Moreover, high cost also makes it difficult to achieve wide applications in the clinic.8 Although the efficacy of new dosage forms of traditional DMARDs, like MTX, has been investigated in a few studies, the results have not been translated into clinical practice.9,10
Iguratimod (IGUR), a methanesulfonanilide, also known as T-614 [N-(3-formylamino-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)], was exclusively developed in countries of the Asia-Pacific region and has been shown to possess anti-inflammatory properties.11 As a novel DMARD, IGUR is effective in treating RA; however, side effects, such as elevated liver enzymes and gastrointestinal discomforts, are the main concerns in its clinical applications.12 IGUR is practically insoluble in aqueous solvents and is only available in oral dosage forms.11 A major problem with oral administration is that the speed and extent of drug absorption are affected by multiple factors, owing to the complex physiological state of the gastrointestinal tract. The low solubility of drugs is responsible for incomplete absorption and low bioavailability, which affects their clinical efficacy and increases its gastrointestinal side effects.13 To alleviate the side effects of IGUR, and to improve its bioavailability and promote its application in the treatment of RA, it is necessary to develop a convenient and effective drug-delivery system for this drug.
In this study, we developed an in situ forming injectable hydrogel drug-delivery system, which was used as a depot of nanoiguratimod (NanoIGUR), for the treatment of RA. We evaluated the biological effects (proliferation, migration, and invasion) of the NanoIGUR-loaded hydrogel on fibroblast-like synoviocytes (RA-FLS). The pharmacokinetics of oral raw IGUR and subcutaneous injection of NanoIGUR-loaded hydrogel was assessed in healthy rats. Furthermore, the efficacy of NanoIGUR-loaded hydrogel in treating collagen-induced arthritis (CIA) rat model was evaluated. Overall, we reported the successful preparation of a new sustained-release NanoIGUR-loaded hydrogel.
Materials And Methods
The raw IGUR was provided by the Simcere Pharmaceutical Group (Jiangsu, China). Adipic acid dihydrazide (ADH, >99.0%), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC, 98%), triethanolamine (TEA, 98%), and polyvinyl alcohol (PVA; average Mw 31,000) were purchased from Shanghai Aladdin Bio-Chem Technology Co. Ltd. (Shanghai, China). Dimethyl sulfoxide (DMSO, AR grade), used as a solvent, was purchased from Beijing Chemical Works (Beijing, China). Sodium hyaluronan (HA; average Mw 50,000) was purchased from Bloomage Freda Biopharm Co. Ltd. (Jinan, China). N-Acryloxysuccinimide (NHS-Ac, 99%) and 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES, 99%) were purchased from J&K Scientific Ltd. (Beijing, China). PEG (Thiol)2 (HS-PEG-SH), with an average Mw of 3500, was purchased from JenKem Technology Co. Ltd. (Beijing, China). All the compounds were used as received.
Hyaluronic Acid–Acrylate Modification
Sodium hyaluronan was modified to contain acrylate functionalities as previously described.14 Briefly, as shown in Figure 1A, HA (2.00 g, 50 kDa, 5.28 mmol carboxylic acid) was reacted with 25.0 g (143.5 mmol) of ADH at pH 4.75 in the presence of 4.0 g (20 mmol) of EDC overnight and purified by dialysis [8000 molecular weight cutoff (MWCO)] in deionized (DI) water for 5 days. The purified intermediate (HA-ADH) was lyophilized and stored at −20°C until used. Approximately 45% of the carboxyl groups were modified with ADH; the modification was characterized using 1H NMR (D2O) by taking the ratio of peaks at δ = 1.54 and 2.26, corresponding to the eight hydrogens of the methylene groups on the ADH, to the singlet peak of the acetyl methyl protons in HA (δ = 1.88) (Figure 1B). All the modified HA-ADH was reacted with NHS-Ac (4.46 g, 26.38 mmol) in HEPES buffer (10 mM HEPES, 150 mM NaCl, 10 mM EDTA, pH 7.2) overnight and purified by dialysis in a 100–0 mM salt gradient for 1 day, followed by dialysis in DI water for 3–4 days before lyophilization. The degree of acrylation was determined to be ~11% using 1H NMR (D2O) by taking the ratio of the multiplet peak at δ = 6.2, corresponding to the cis and trans acrylate hydrogens to the singlet peak of the acetyl methyl protons in HA (δ = 1.88) (Figure 1B). Dynamic mechanical thermal analysis (DMTA-V, Rheometric Scientific, USA) was used to analyze the loss modulus (E’) and storage modulus (E’’) of NDHM, and the tests were run from 0.01 Hz to 10 Hz at 37 °C.
Figure 1 Synthesis scheme for hyaluronic acid–acrylate (HA-AC) (A) and the results of NMR (B). a:-CH3, b:-CH2-CO-, c:-CH2, and d: -CH.
Preparation Of NanoIGUR By Liquid Antisolvent Precipitation
NanoIGUR, with high aqueous phase dispersibility, was synthesized using the liquid antisolvent precipitation (LAP) method. Briefly, 20 mg of the raw IGUR and 20 mg of PVA were dissolved in 1 mL of DMSO as the drug solution. One milliliter of the drug solution was quickly added to 20 mL of ultrapure water (antisolvent), and then the mixture was stirred for 30 mins. After dialysis and lyophilization, the powder was stored at 4°C for further use.
Characterizations Of NanoIGUR
The particle size of NanoIGUR was determined by dynamic light scattering (Nano ZS, Malvern Instruments, UK) and reported as the Z-average (intensity-based mean particle diameter). The measurements were repeated three times. The morphology of the samples was examined using a transmission electron microscope (TEM, Hitachi HT7700, Japan). The drug-loading capacity (DLC) and dissolution rate of the sample were determined using a UV/visible spectrophotometer (Varian Cary 50, USA) at a wavelength of 309 nm, according to the formula:
DLC (wt. %) = (weight of the drug/weight of drug-polymer nanoparticles) × 100
Evaluation Of In Vitro Drug Release
The dissolution rate of raw IGUR and NanoIGUR in PBS buffer (150 mM, pH 7.4) at 37°C was determined. In each experiment, 1.0 mg of the sample was mixed with 5 mL of PBS buffer and was fully dispersed. The mixture was then transferred into a dialysis bag (3500 MWCO), and the bag was put into a tube containing 20 mL of PBS buffer. Further, 3 mL of PBS buffer was withdrawn from the tube at predetermined periods of time, and 3 mL of fresh buffer was added into the tube. The dissolution rate of raw IGUR and NanoIGUR was calculated by determining the UV absorption of IGUR at 309 nm. The NanoIGUR-loaded hydrogel was prepared by first dissolving the polymers, HA-AC and HS-PEG-SH, using the NanoIGUR solution. Subsequently, equivalent volumes and concentrations of the two solutions were mixed for allowing the gelation. The process for the solidification of NanoIGUR-loaded hydrogel is shown in Figure 2C. The resulting hydrogels (250 μL) were loaded into a dialysis bag (3500 MWCO), and the dialysis bag was put into a tube containing 20 mL of PBS buffer. Further, 3 mL of PBS buffer was withdrawn from the tube at predetermined periods of time, and 3 mL of fresh buffer was added into the tube. The dissolution rate of IGUR from the hydrogel was calculated by determining the UV absorption of IGUR at 309 nm.
Synovial specimens were taken from five patients with RA who underwent synovectomy or joint replacement at Peking University Third Hospital. All the patients met the 2010 ACR/EULAR classification criteria for RA.15 RA-FLS were isolated from the fresh synovial tissues as previously described.16 After the synovial tissue was obtained, the excess adipose tissue was removed immediately, and the synovial tissue was infiltrated into high glucose DMEM (GIBCO-BRL) with 15% FBS (GIBCO-BRL), 100 U/mL penicillin (GIBCO), and 100 μg/mL streptomycin (GIBCO) after three times of irrigation with PBS. The synovial tissue was cut into tissue fragments about 2 mm × 2 mm in size and then inoculated in the flask and added 2 mL DMEM containing 20% FBS. The flask was reversed after incubation at 37°C and 5% CO2 incubator for 6-10 hrs. Primary cell growth could be seen after 5–7 days and RA-FLS from passages three to six was used in this study. This study was conducted in accordance with the ethical principles originating in the Declaration of Helsinki (2004 revision) and was approved by the Ethics Committee of Peking University Third Hospital (No. LA2015044-02), and all the patients provided signed informed consent.
Vitro MTS Assay
In addition to the blank controls (10% FBS high glucose DMEM complete medium) and the sham controls (complete medium containing PBS for the raw IGUR or blank gel for the NanoIGUR-loaded hydrogel), different concentrations (40, 80, 160, and 320 μg/mL) of raw IGUR or NanoIGUR-loaded hydrogel were used for cell proliferation experiments. Cells were seeded (3×103 cells/100 μL) and incubated overnight to allow cell adherence. Six duplicate wells were assigned for each group. After 48 hr incubation with different concentrations of raw IGUR or NanoIGUR-loaded hydrogel, 20 μL MTS was added to each well. Subsequently, after further incubation for 2 hrs, the absorbance (OD) was measured at 490 nm and analyzed statistically.
Vitro Migration Assay
The transwell plate was pre-balanced before the migration experiment and the drug concentration gradient was set as in the MTS assay. RA-FLS in serum-free medium (3×103 cells/100 μL) was added to the upper chamber of 8-μm pore size transwell chambers (Corning). The bottom chambers contained 10% FBS as a chemoattractant, and different concentrations of raw IGUR or NanoIGUR-loaded hydrogel were separately added into the upper chambers. Cells were allowed to migrate through the porous membrane for 48 hrs at 37°C. Nonmigrating cells that remained on the upper surface of the filter were removed with cotton swabs, and the remaining cells on the lower surface of the filter were fixed with 600 μL 4% paraformaldehyde at room temperature for 30 mins, stained with 600 μL 0.1% crystal violet and counted under a bright field microscope (Nikon E400). Five visual fields were randomly selected for counting, and each experiment was independently performed three times.
Vitro Invasion Assay
The matrigel matrix (Invitrogen) was converted into a liquid state before the invasion experiment. The matrix glue was diluted with precooled serum-free medium (medium: matrix glue = 5:1) and 60 μL of it was added to each compartment. Incubation was done overnight in an incubator. The remaining steps were the same as in the migration experiments. Five visual fields were randomly selected for counting and three independent replications of the experiment were conducted.
The animal study was approved by the Peking University Animal Protection and Ethics Committee (No. LA201425) and strictly abided by the Laboratory Animal Protection and Use guidelines. Female Lewis rats (150 ± 10 g, 6 weeks) were purchased from Vital River Laboratory Animal Technology Co. Ltd (Beijing, China). Prior to the experiments, all the animals were housed in specific pathogen-free animal rooms under controlled temperature (23 ± 2°C) and 12-hr light/dark cycles for at least 7 days and had free access to diet and water.
Normal female Lewis rats were used for studying the pharmacokinetics of IGUR. The drug concentration in plasma was determined by high-performance liquid chromatography (HPLC) after administration of a single dose (10 mg/kg) of IGUR. The rats in the raw IGUR group were orally administered raw IGUR dissolved in 0.5% carboxymethyl-cellulose (CMC) sodium in distilled water. Serial blood samples were collected in heparinized tubes at 10 and 30 mins, and at 1, 2, 3, 4, 6, 8, 12, 18, and 24 hrs. The rats in the NanoIGUR-loaded hydrogel group were subcutaneously injected with NanoIGUR-loaded hydrogel and blood samples were collected at 10 and 30 mins, and at 1, 2, 3, 4, 6, 8, 12, 18, 24, 48, 72, 96, and 120 hrs in heparinized tubes, as described by Xiaofeng Guo et al.17 The pharmacokinetic parameters were processed by DAS 2.0 software and calculated according to the characteristics of the pharmacokinetic–time curve.
Collagen-Induced Arthritis (CIA) Model
CIA is an ideal animal model for RA.18 To induce CIA, bovine type II collagen (Chondrex, WDC, USA, 20,022) was dissolved in an equal volume of Freund’s complete adjuvant (Chondrex, WDC, USA, 7001), and a total volume containing 400 μg collagen was subcutaneously injected to each rat. Seven days later, immunization was repeated with bovine type II collagen and incomplete Freund’s adjuvant (Chondrex, WDC, USA, 7002). After 14 days, the incidence of arthritis was observed and recorded daily. The severity of CIA joint inflammation was evaluated as the arthritis index (AI) score.19 Briefly, the severity of arthritis in each paw was rated from 0 (normal) to 4 (severe). The AI score of the onset joint was added, with a maximum score of 16. The scoring was performed independently by two researchers.
Vivo Therapeutic Efficacy
The CIA rats were randomly allocated to three groups. No intervention was done in one group (CIA model, n = 7), whereas rats in the other two groups received the drugs as follows: raw IGUR 10 mg/kg intragastrically, daily (raw IGUR, n = 7) and the NanoIGUR-loaded hydrogel 10 mg/kg by subcutaneous injection, every 3 days (NanoIGUR-loaded hydrogel, n = 7). The healthy normal rats were used as healthy controls (healthy control, n = 7). In this study, 0.5% CMC was used as a suspension agent for raw IGUR to increase the distribution area of IGUR in the gastrointestinal tract after oral administration, and made it absorb thoroughly. Experiments have confirmed that 0.5% CMC has no toxic side effects on experimental animals.20 HA is a ubiquitous natural polysaccharide in the body with excellent physicochemical properties such as biodegradable, biocompatible, nontoxic, and nonimmunogenic characteristics. Accordingly, HA has been widely used for various medical applications such as arthritis treatment21, ophthalmic surgery22, drug delivery,23,24 and tissue engineering,25 So we did not set up a group for CIA treated with 0.5% CMC or the blank hydrogel in the study. The total duration of drug administration was 21 days. Weight, ankle diameters, and AI scores of the experimental animals were measured every 3 days by two researchers.
After drug intervention, the rats were euthanized by exsanguination under anesthesia and the right ankles were harvested for histological evaluation. The tissue was fixed, decalcified, and dehydrated before being embedded in paraffin. H&E staining and saffron O-fixing green staining were performed to observe the histological changes. Hyperplasia of synovial tissue and blood vessels, infiltration of lymphocytes, and destruction of bone and cartilage were observed under a light microscope. The same sample was scored in terms of the Mankin’s score (5 grades) based on observations of multiple visual fields, several times.26 The total semiquantitative score of the pathological injury of ankle joints was calculated.27
Analysis Of The Expression Of Inflammatory Cytokines In Serum And Synovial Homogenate Supernatants By Enzyme-Linked Immunosorbent Assay (ELISA)
Blood was taken from the canthus of the rats and centrifuged at 300 × g for 10 mins. Serum was collected and stored at −80°C. Synovial tissue was isolated and homogenized in PBS containing protease inhibitors (Applygen, China) and centrifuged, and the supernatant was collected. The levels of interleukin-1 beta (IL-1β), interleukin-1 (IL-6), and TNF-α were determined using high-sensitivity ELISA kits according to the manufacturer’s instructions (MultiScience, China).
Statistical analysis was performed using SPSS V.22.0. Data were expressed as means ± SD. Mann–Whitney U-test or ANOVA analyses were used to compare the differences between the groups. A value of P < 0.05 was considered to indicate a statistically significant difference.
Preparation And Characterization Of NanoIGUR
NanoIGUR with an IGUR : PVA weight ratio of 1:1 and a solvent : antisolvent ratio of 1:20 was prepared using the LAP technique. The TEM image revealed a spherical shape of NanoIGUR particles, ranging in size from 300 to 530 nm (Figure 3A). The average size of NanoIGUR, as determined using DLS, was 458 nm (Figure 3B), which was consistent with the TEM results. As shown in Figure 3C, E′ was consistently higher than E″ (E′=storage modulus, E″=loss modulus), and they exhibited a plateau in the entire frequency range of 0.01 to 10 Hz at 37°C, suggesting that the hydrogels were robust and behaved as elastic solids.
Vitro Drug Release
The contents of IGUR in NanoIGUR and NanoIGUR-loaded hydrogel were measured using UV spectrophotometry. The drug-loading capacity of NanoIGUR was estimated to be 34.98%. The loading efficiency further confirmed the combination of IGUR with the PVA excipient during the LAP process to form IGUR/PVA nanocomplexes. The comparison of the dissolution rates of raw IGUR and NanoIGUR prepared by the LAP method is shown in Figure 3D. Only 28.65% of raw IGUR was dissolved during the 72 hr incubation period. In contrast, the LAP method effectively reduced the particle size of NanoIGUR, leading to a much higher dissolution rate of 80% and a very fast release equilibrium period of 24 hrs. The results proved that smaller particle size could improve the solubility owing to the increased surface area available for dissolution, as described by the Noyes–Whitney equation.28 Therefore, using the LAP technique is effective in improving the solubility and bioavailability of water-insoluble drugs.
NanoIGUR-loaded hydrogel was prepared by mixing the HA-AC solution containing NanoIGUR with the HS-PEG-SH cross-linker solution, and this mixture was completely solidified after 5 mins, suggesting that the hydrogel formation time would be quick enough for in vivo applications. The drug dissolution profile of NanoIGUR-loaded hydrogel is shown in Figure 3D. IGUR was gradually released from the hydrogel matrix and the release could be sustained for 72 hrs, with a dissolution rate of 68%. This suggests that the hydrogel composite can serve as a reservoir for sustained release of the encapsulated drug over a long term.
Effects Of Different Dosage Forms Of IGUR On Proliferation, Migration, And Invasion Of RA-FLS
In vitro drug release tests confirmed that the dissolution of the NanoIGUR-loaded hydrogel reached a plateau of release at 48 hrs. So, the in vitro cell proliferation, migration, and invasion experiments of RA-FLS were all conducted at 48 hrs. MTS assay has confirmed that NanoIGUR-loaded hydrogel could inhibit the proliferation of the RA-FLS in a dose-dependent manner. Furthermore, 160 μg/mL NanoIGUR-loaded hydrogel had better inhibitory effect than the same concentration of raw IGUR (relative cell proliferation ratio: 83.72 ± 1.41% for raw IGUR; 74.25 ± 1.17% for NanoIGUR-loaded hydrogel) and so did 320 μg/mL NanoIGUR-loaded hydrogel (relative cell proliferation ratio: 80.73 ± 2.14% for raw IGUR; 65.25 ± 2.31% for NanoIGUR-loaded hydrogel) (Figure 4A). Moreover, the different dosage forms of IGUR could inhibit migration and invasion of RA-FLS, with NanoIGUR-loaded hydrogel showing a better inhibitory effect than raw IGUR in the 160 and 320 μg/mL groups. For example, relative cell migration and invasion ratio for 320 μg/mL NanoIGUR-loaded hydrogel treated group were 22.42 ± 1.96% and 20.74 ± 1.16%, respectively, while the relative cell migration and cell invasion ratio for raw IGUR group were 44.69 ± 1.58% and 44.59 ± 2.24%, respectively. After excluding the effect of NanoIGUR-loaded hydrogel on cell proliferation, it still inhibit-ed the migration and invasion of RA-FLS (Figure 4B and C). Representative pictures are shown in Figure 4D and E.
Plasma Concentration And Pharmacokinetic Parameters
The plasma concentration–time curves for healthy rats after oral administration of raw IGUR and subcutaneous injection of NanoIGUR-loaded hydrogel (10 mg/kg) are shown in Figure 5A. The pharmacokinetic parameters were processed using the DAS 2.0 software. The T1/2 of NanoIGUR-loaded hydrogel was determined to be 13.7 hrs, which was more than the T1/2 of raw IGUR (3.7 hrs). The Cmax of NanoIGUR-loaded hydrogel was 5921.9 μg/mL, which was lower than that of raw IGUR (12,654.6 μg/mL). The AUClast of NanoIGUR-loaded hydrogel and raw IGUR were 150,171.9 and 110,670 μg/mL, respectively. The lower Cmax and delayed Tmax indicated the sustained-release characteristics of NanoIGUR-loaded hydrogel and the higher value of AUClast suggested better bioavailability.29–31
Changes In Body Weight, Ankle Joint Diameter, And AI Scores After Drug Intervention In CIA Models
According to the pharmacokinetic parameters, NanoIGUR-loaded hydrogel (10 mg/kg) was injected subcutaneously in rats every 3 days, and raw IGUR was given intragastrically daily for 21 days. The weight, ankle joint diameter, and AI scores were recorded every 3 days. As shown in Figure 5B, the AI scores in the NanoIGUR-loaded hydrogel group were significantly lower than in the CIA group on the 10th day of administration, and the difference was statistically significant. The AI scores in the raw IGUR group were significantly lower than in the CIA group on the 16th day of administration. From the 4th day of administration, the mean diameters of the ankle joints in the NanoIGUR-loaded hydrogel and raw IGUR groups were significantly smaller than in the CIA group, and this was maintained until the end of the administration (Figure 5C). On the 13th day of administration, the body weights in the NanoIGUR-loaded hydrogel and raw IGUR groups were significantly higher than in the CIA group, but were lower than in the healthy control group (Figure 5D). Representative pictures of rat ankle joints are shown in Figure 5E. These data indicate that NanoIGUR-loaded hydrogel and raw IGUR have similar therapeutic effects on CIA rats.
The H&E-stained sections of ankle joints of rats were observed under a light microscope. In the control group, normal ankle joint structure, with smooth and intact articular cartilage surface and normal joint space, without synovial tissue proliferation or pannus formation was observed. In the CIA group, the ankle joint structure was severely destroyed, with hyperplastic synovial tissue, infiltrated inflammatory cells, pannus formation, and bone erosion were observed. The articular cartilage surface was damaged, the surface was stripped, and the joint space was narrowed. Compared with the CIA group, rat ankle joints from the raw IGUR and NanoIGUR-loaded hydrogel treated groups showed less infiltration of inflammatory cells in the synovial tissue and no obvious bone erosion (Figure 6A). The synovitis scores and Mankin’s scores in the raw IGUR and NanoIGUR-loaded hydrogel groups were significantly lower (P < 0.05) than in the CIA group, but there was no significant difference in the scores between the raw IGUR and NanoIGUR-loaded hydrogel groups (Figure 6C and D). The saffron O-fixing green staining showed that the basophilic cartilage stained red with saffron O and the acidophilic bone stained green or blue with the acid dye, thus distinguishing the cartilage tissue from the bone tissue. A complete cartilage band attached to the articular surface was observed in the healthy control group, whereas in the CIA group, the cartilage band on the articular surface almost disappeared, indicating that the entire cartilage layer was eroded. In the raw IGUR and NanoIGUR-loaded hydrogel groups, the cartilage on the articular surface was slightly thinner or wormlike, but the cartilage band remained intact or only a small amount of cartilage was eroded and lost, showing a slight discontinuity. Compared to the CIA group, the pathological changes in the ankle joint cartilage of rats in the raw IGUR and NanoIGUR-loaded hydrogel groups were significantly improved (Figure 6B). The percentage of cartilage area in each group was estimated using Image J software. Compared with the normal control group, the area of ankle cartilage in the CIA group was significantly reduced (P < 0.001). The area of ankle cartilage in the CIA rats increased significantly after drug intervention (raw IGUR and NanoIGUR-loaded hydrogel) (P < 0.05), but there was no statistical difference between the raw IGUR and NanoIGUR-loaded hydrogel groups (Figure 6E).
Expression Of Inflammatory Cytokines After Drug Intervention
IL-1β, IL-6, and TNF-α are crucial inflammatory cytokines in the process of inflammation in RA and are associated with the disease activity.32–34 Compared with the control group, IL-6, TNF-α, and IL-1β levels in the serum of the CIA group were significantly upregulated. The serum levels of IL-6, TNF-α, and IL-1 β in the raw IGUR and NanoIGUR-loaded hydrogel groups were significantly lower than those in the CIA group, but there was no significant difference between the raw IGUR and NanoIGUR-loaded hydrogel groups (Figure 7A–C). Similar results were found in the synovial tissue homogenate supernatant (Figure 7D–F). Overall, these results demonstrate the efficacy of NanoIGUR-loaded hydrogel in the treatment of CIA rats. Subcutaneous injection of 10 mg/kg NanoIGUR-loaded hydrogel every 3 days achieved the same therapeutic effect as the oral administration of 10 mg/kg raw IGUR daily.
Compared with the conventional administration, the sustained release of drugs has several advantages. It allows the maintenance of effective therapeutic concentration of the drug in body fluids for a longer time and reduces the times of administration, which is convenient for the patients. Moreover, it reduces the peak–valley of the drug concentration in the blood, reducing the side effects and improving the curative effects, and increases the stability of the drug. Sustained release of drugs also allows reduction in the dose and direct administration to specific target organs, which decreases the systemic side effects. Injectable hydrogels for in vivo localized drug delivery have achieved remarkable results in the development of new dosage forms that are not possible through traditional drug delivery and have shown huge prospects in the drug market, which has rapidly made them one of the most popular pharmaceutical dosage forms.35–37
Although the injectable hydrogel in vivo localization dosage form has many advantages, there are presently some limitations in its use.38–40 The even distribution and stabilization of water-insoluble drugs in the hydrogel matrix is a key issue that needs to be resolved for the construction of hydrogel dosage forms. Therapeutic drugs are mostly hydrophobic molecules,41–44 and the hydrogel has a certain network pore size. Therefore, only when a hydrophobic drug can easily be dispersed into particles, having a size larger than that of the hydrogel pore, can it be uniformly and stably restricted. In the hydrogel matrix, it is further released from the hydrogel uniformly and constantly by passive diffusion of molecules and by the degradation of the hydrogel host material. The liquid antisolvent technology is a new method for preparing nanomicron powders, which has been proposed in recent years, especially for the preparation of nanomicron drugs, and has shown prospects for broad application.45 Based on the molecular mixing theory, the fast molecular mixing characteristics in the liquid environment can effectively and accurately control the synthesis of drug particles. Thus, drug nanoparticles with high nanometer size and uniform particle size can be synthesized, and nanomedicines with excellent dispersion properties, high dissolution, and high bioavailability in the aqueous phase can be prepared by controlling the particle size and using the dispersant.
IGUR is used in the treatment of RA, but gastrointestinal side effect caused by conventional oral dosage forms limits its application. For the first time, we tried to develop a new dosage form of IGUR to alleviate its side effects and to satisfy the needs of clinical therapy. As shown in Figure 2, first, NanoIGUR with high aqueous phase dispersibility was synthesized using the LAP method. Subsequently, we prepared HA-ADH, with amino group from HA and ADH, by condensation reaction, and then reacted it with N-acryloyloxysuccinimide to obtain a double bond on the segment of HA-AC. Furthermore, HA-AC was completely dissolved in PBS buffer and sequentially mixed with NanoIGUR and the crosslinking agent PEG (Thiol)2 (HS-PEG-SH) to prepare a hydrogel precursor solution. After subcutaneous injection, hydrogels encapsulating NanoIGUR were formed in situ by Michael addition reaction.46–48
After the preparation of the new dosage form of NanoIGUR-loaded hydrogel, we first determined its effects on the proliferation, migration, and invasion of RA-FLS. The NanoIGUR-loaded hydrogel showed better inhibitory effect than raw IGUR generally in the 160 and 320 μg/mL groups, which indicated that the NanoIGUR-loaded hydrogel improved the solubility of the water-insoluble IGUR and might act as a new drug-delivery system for future clinical applications. Thereafter, the plasma concentration and pharmacokinetic parameters of raw IGUR and NanoIGUR-loaded hydrogel were tested in healthy rats. The pharmacokinetics of the NanoIGUR-loaded hydrogel indicated that intermittent subcutaneous administration is feasible, which might improve the compliance of patients by reducing the number of administrations and the risk of gastrointestinal side effects. According to the pharmacokinetic parameters, NanoIGUR-loaded hydrogel (10 mg/kg) was injected subcutaneously in CIA models of rats every 3 days, and raw IGUR was given intragastrically, daily. Changes in body weight, ankle joint diameter, and AI score after 21 days of drug intervention indicated that NanoIGUR-loaded hydrogel and raw IGUR had similar therapeutic effects on the CIA rat models. By changing the route of administration, the same effect and longer interval of administration could be achieved, which shows that the new drug-delivery system—the NanoIGUR-loaded hydrogel, is suitable for animal experiments and may have good prospects for clinical applications in the future. Histological evaluation has further confirmed that both raw IGUR and NanoIGUR-loaded hydrogel could effectively reduce the destruction of cartilage and bone in the ankle joints of CIA rats and could reduce the proliferation of synovium and infiltration of inflammatory cells in the synovial tissue.
IL-1β, IL-6, and TNF-α are crucial inflammatory cytokines in the process of inflammation in RA and are associated with the disease activity. The expression levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) in the serum and supernatant of the synovial tissue homogenate demonstrate the efficacy of NanoIGUR-loaded hydrogel in the treatment of CIA rats. Subcutaneous injection of 10 mg/kg NanoIGUR-loaded hydrogel every 3 days achieved the same therapeutic effect as the oral administration of 10 mg/kg raw IGUR daily. By changing the dosage form of IGUR into NanoIGUR-loaded hydrogel, we reduced the dosage of raw drugs, achieved long-term and sustained release, and acquired the same therapeutic effect. Although it is not ideal to apply the three-day administration of NanoIGUR-loaded hydrogel in clinical application, our research provides a kind of new thinking and method. Further improvements in the composition of hydrogels may extend the interval of administration.
RA is a common systemic autoimmune disease characterized by erosive synovitis, which leads to the damage of the joint architecture and consequent disability. Early treatment with DMARDs is the key to prevent joint destruction and improve prognosis. As a novel type of DMARD, IGUR is effective in treating RA by inhibiting the secretion of polyclonal immunoglobulin and production of cytokines.49 At present, only oral-administered IGUR tablets are available because of its hydrophobic properties. The prevalence of gastrointestinal side effects limits the use of IGUR in clinical practice. The designing of a sustained and localized drug-delivery system for subcutaneous or intra-articular administration may increase its use by improving the bioavailability and by preventing gastrointestinal irritation. To achieve this goal, a new drug-delivery system, the nanoloaded hydrogel, was developed, and in vitro and in vivo experiments confirmed it to be an effective drug-delivery system. NanoIGUR-loaded hydrogel released IGUR in a sustained manner with long-acting time, and its subcutaneous injection achieved similar efficacy in treating CIA rats as did the oral administration of raw IGUR. However, the biocompatibility, biodegradability, and clinical safety of the new hydrogel carrier need to be further studied in the future. Overall, the NanoIGUR-loaded hydrogel may serve as a new drug-delivery system for specific DMARDs with broad prospects for clinical application.
We gratefully acknowledge the helpful discussions with Professor Xueqing Wang on the animal pharmacokinetic experiments. This work was financially supported by the National Natural Science Foundation of China (Grant 21476018, Grant 21622601, Grant 51972339, and Grant 81571573), the National Key R&D Program of China (Grant 2015CB932101), and the Open Project Program of the State Key Laboratory of Organic-Inorganic Composites, Beijing University of Chemical Technology (Grant oic-201901010).
The authors report no conflicts of interest in this work.
1. Mahajan TD, Mikuls TR. Recent advances in the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2018;30(3):231–237.doi:10.1097/BOR.0000000000000496
2. Komatsu N, Takayanagi H. [Bone and cartilage destruction in rheumatoid arthritis]. Clin Calcium. 2012;22(2):179–185. doi:CliCa1202179185
3. Corbacho MI, Dapueto JJ. Assessing the functional status and quality of life of patients with rheumatoid arthritis. Rev Bras Reumatol. 2010;50(1):31–43. doi:10.1590/S0482-50042010000100004
4. Goekoop-Ruiterman YP, Huizinga TW. Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA? Nat Rev Rheumatol. 2010;6(2):68–70. doi:10.1038/nrrheum.2009.253
5. Osiri M, Deesomchok U, Tugwell P. Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice. Clin Rheumatol. 2006;25(5):721–727. doi:10.1007/s10067-005-0155-4
6. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11 Suppl 1: S1.doi:10.1186/ar2666
7. Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet. 2002;359(9306):540–541. doi:10.1016/S0140-6736(02)07718-8
8. Chou CT. The high cost of anti-TNFalpha drugs for rheumatoid arthritis: can a low-price product be developed in the future? J Chin Med Assoc. 2012;75(2):51–53. doi:10.1016/j.jcma.2011.12.012
9. Mello SB, Tavares ER, Bulgarelli A, Bonfa E, Maranhao RC. Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigen-induced arthritis. Int J Nanomedicine. 2013;8:443–449. doi:10.2147/IJN.S29392
10. Prabhu P, Shetty R, Koland M, et al. Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity. Int J Nanomedicine. 2012;7:177–186. doi:10.2147/IJN.S25310
11. Mucke HA. Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today (Barc). 2012;48(9):577–586. doi:10.1358/dot.2012.48.9.1855758
12. Li J, Mao H, Liang Y, et al. Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis. Clin Dev Immunol. 2013;2013:310628. doi:10.1155/2013/310628
13. Jinno J, Kamada N, Miyake M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006; 111 (1–2): 56–64. doi:10.1016/j.jconrel.2005.11.013
14. Tokatlian T, Cam C, Siegman SN, Lei Y, Segura T. Design and characterization of microporous hyaluronic acid hydrogels for in vitro gene transfer to mMSCs. Acta Biomater. 2012;8(11):3921–3931. doi:10.1016/j.actbio.2012.07.014
15. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012;51 Suppl 6: vi5–vi9. doi:10.1093/rheumatology/kes279
16. Zimmermann T, Kunisch E, Pfeiffer R, et al. Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture–primary culture cells markedly differ from fourth-passage cells. Arthritis Res. 2001;3(1):72–76. doi:10.1186/ar142
17. Zhou T, Ding L, Li X, et al. Determination of iguratimod in rat plasma by high performance liquid chromatography: method and application. Biomed Chromatogr. 2008;22(3):260–264. doi:10.1002/bmc.921
18. Hirose J, Tanaka S. [Animal models for bone and joint disease. CIA, CAIA model]. Clin Calcium. 2011;21(2):253–259. CliCa1102253259
19. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 1980;283(5748):666–668. doi:10.1038/283666a0
20. Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol. 2006;41(5):798–806. doi:10.1016/j.yjmcc.2006.07.004
21. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;39:3–9.
22. Balazs EA. Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg Technol Int. 2004;12:278–289.
23. Hahn SK, Kim SJ, Kim MJ, Kim DH. Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. Pharm Res. 2004;21(8):1374–1381. doi:10.1023/b:pham.0000036910.41224.de
24. Kim SJ, Hahn SK, Kim MJ, Kim DH, Lee YP. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J Control Release. 2005;104(2):323–335. doi:10.1016/j.jconrel.2005.02.012
25. Ohri R, Hahn SK, Hoffman AS, Stayton PS, Giachelli CM. Hyaluronic acid grafting mitigates calcification of glutaraldehyde-fixed bovine pericardium. J Biomed Mater Res A. 2004;70(2):328–334. doi:10.1002/jbm.a.30088
26. Kuroki H, Nakagawa Y, Mori K, et al. Acoustic stiffness and change in plug cartilage over time after autologous osteochondral grafting: correlation between ultrasound signal intensity and histological score in a rabbit model. Arthritis Res Ther. 2004;6(6):R492–504. doi:10.1186/ar1219
27. Krenn V, Morawietz L, Burmester GR, et al. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology. 2006;49(4):358–364. doi:10.1111/j.1365-2559.2006.02508.x
28. Horn D, Rieger J. Organic nanoparticles in the aqueous phase-theory, experiment, and use. Angew Chem Int Ed Engl. 2001;40(23):4330–4361. doi:10.1002/1521-3773(20011203)40:23<4330::AID-ANIE4330>3.0.CO;2-W
29. Silber BM, Rao S, Fife KL, et al. Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice. Pharm Res. 2013;30(4):932–950. doi:10.1007/s11095-012-0912-4
30. Rausch-Derra LC, Rhodes L, Freshwater L, Hawks R. Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs. J Vet Pharmacol Ther. 2016;39(6):566–571. doi:10.1111/jvp.12306
31. Portoles A, Almeida S, Terleira A, et al. Truncated AUC in the evaluation of fluconazole bioequivalence. A cross-over, randomised, open-label study in healthy volunteers. Arzneimittelforschung. 2004;54(11):752–756. doi:10.1055/s-0031-1297032
32. Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan YX, Jiang YF. Plasma levels of IL-37 and correlation with TNF-alpha, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. PLoS One. 2014;9(5):e95346. doi:10.1371/journal.pone.0095346
33. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31(6):784–788. doi:10.1002/art.1780310614
34. Lettesjo H, Nordstrom E, Strom H, et al. Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand J Immunol. 1998;48(3):286–292. doi:10.1046/j.1365-3083.1998.00399.x
35. Lee F, Chung JE, Kurisawa M. An injectable hyaluronic acid-tyramine hydrogel system for protein delivery. J Control Release. 2009;134(3):186–193. doi:10.1016/j.jconrel.2008.11.028
36. Nakaji-Hirabayashi T, Kato K, Iwata H. Hyaluronic acid hydrogel loaded with genetically-engineered brain-derived neurotrophic factor as a neural cell carrier. Biomaterials. 2009;30(27):4581–4589. doi:10.1016/j.biomaterials.2009.05.009
37. Lei Y, Huang S, Sharif-Kashani P, Chen Y, Kavehpour P, Segura T. Incorporation of active DNA/cationic polymer polyplexes into hydrogel scaffolds. Biomaterials. 2010;31(34):9106–9116. doi:10.1016/j.biomaterials.2010.08.016
38. Liu J, Qi C, Tao K, et al. Sericin/dextran injectable hydrogel as an optically trackable drug delivery system for malignant melanoma treatment. ACS Appl Mater Interfaces. 2016;8(10):6411–6422. doi:10.1021/acsami.6b00959
39. Liu M, Song X, Wen Y, Zhu JL, Li J. Injectable thermoresponsive hydrogel formed by alginate-g-poly(N-isopropylacrylamide) that releases doxorubicin-encapsulated micelles as a smart drug delivery system. ACS Appl Mater Interfaces. 2017;9(41):35673–35682. doi:10.1021/acsami.7b12849
40. Thambi T, Li Y, Lee DS. Injectable hydrogels for sustained release of therapeutic agents. J Control Release. 2017;267:57–66. doi:10.1016/j.jconrel.2017.08.006
41. Kang L, Gao Z, Huang W, Jin M, Wang Q. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharm Sin B. 2015;5(3):169–175. doi:10.1016/j.apsb.2015.03.001
42. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3(9):785–796. doi:10.1038/nrd1494
43. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3–19. doi:10.1016/S0169-409X(00)00118-6
44. Hu J, Johnston KP, Williams RO,
45. Cushing BL, Kolesnichenko VL, O’Connor CJ. Recent advances in the liquid-phase syntheses of inorganic nanoparticles. Chem Rev. 2004;104(9):3893–3946. doi:10.1021/cr030027b
46. Elbert DL, Pratt AB, Lutolf MP, Halstenberg S, Hubbell JA. Protein delivery from materials formed by self-selective conjugate addition reactions. J Control Release. 2001; 76 (1–2): 11–25. doi:10.1016/S0168-3659(01)00398-4
47. Shu XZ, Ahmad S, Liu Y, Prestwich GD. Synthesis and evaluation of injectable, in situ crosslinkable synthetic extracellular matrices for tissue engineering. J Biomed Mater Res A. 2006;79(4):902–912. doi:10.1002/jbm.a.30831
48. Lei Y, Gojgini S, Lam J, Segura T. The spreading, migration and proliferation of mouse mesenchymal stem cells cultured inside hyaluronic acid hydrogels. Biomaterials. 2011;32(1):39–47. doi:10.1016/j.biomaterials.2010.08.103
49. Tanaka K, Yamamoto T, Aikawa Y, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford). 2003;42(11):1365–1371. doi:10.1093/rheumatology/keg381
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]